Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Laurent Garderet*, Dimitris Ziagkos, Anja van Biezen, Simona Iacobelli, Jürgen Finke, Johan Maertens, Liisa Volin, Per Ljungman, Patrice Chevallier, Jakob Passweg, Nicolaas Schaap, Dietrich Beelen, Arnon Nagler, Didier Blaise, Xavier Poiré, Ibrahim Yakoub-Agha, Stig Lenhoff, Charles Craddock, Rik Schots, Alessandro RambaldiJaime Sanz, Pavel Jindra, Ghulam J. Mufti, Marie Robin, Nicolaus Kröger

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    11 Citations (Scopus)


    The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

    Original languageEnglish
    Publication statusAccepted/In press - 1 Jan 2018


    • Allogeneic stem cell transplantation
    • Del (5q)
    • MDS


    Dive into the research topics of 'Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion'. Together they form a unique fingerprint.

    Cite this